New MRI-Guided radiation aims to zap abdominal tumors with fewer side effects

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Patients with diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (e.g. gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynaecological malignancy. Oligometastatic disease with controlled primary disease\* and maximum total of 5 metastatic lesions in a maximum of 2 different organ systems in any of the following sites: 1. Liver 2. Adrenal 3. Abdomino-pelvic lymph node 4. Other abdominal site e.g. pancreatic, renal. 5. Other pelvic site 6. Bony or lung is allowed only if in conjunction with an abdominal site above * De novo or metachronous oligometastatic disease where the original tumour site has been treated with curative intent. * Controlled primary disease in metachronous oligometastastic disease defined as at least 3 months since original tumour treated with curative intent and no progression at primary site * Controlled primary disease in de novo oligometastatic disease defined as primary tumour site treated with curative intent and no progression at primary site * Oligometastatic disease: Histological confirmation of primary malignancy (histological confirmation of metastasis is not mandatory but should be performed in any situation where there is any diagnostic uncertainty). * All oligometastatic sites treatable with SABR. OR * Patients with oligo-progressive / oligo-persistent disease in maximum total of 2 oligo-progressive abdominal metastases and in a maximum 2 different organ systems * Visible imaging defined targets and suitable for treatment with SABR * Childs Pugh A to B7 (in case of liver treatment) * ECOG 0 -2 * Patient consented Exclusion Criteria: * Contra-indication to MRI * Previous high dose radiotherapy to a site requiring stereotactic treatment (including SIRTEX). Further SABR treatment of lesions previously treated with SABR or high dose radiotherapy is not permitted in this trial. * Substantial overlap with a previously treated high dose (definitive or stereotactic dose) radiation volume. * Primary prostate cancer, carcinoid tumours, germ cell tumours, lymphoma, small cell tumours * Pregnant women * Complete response of metastatic disease to systemic therapy (i.e. no target for SABR) * Competing medical co-morbidity with a more limited prognosis than the cancer diagnosis